GSK Spins Out Pain Assets Into Convergence
This article was originally published in Start Up
The first spin-out company to result from GlaxoSmith-Kline PLC’s exit from key CNS areas including pain and depression was announced on October 4. UK-based Convergence Pharmaceuticals Ltd. raised $35.4 million (£22.4 million) in one of Europe’s largest Series A rounds.
You may also be interested in...
At its latest R&D review, GSK has culled three of its biotech-like discovery performance units and created four new ones. But less important than the numbers is the new culture, claims CEO Andrew Witty
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.
Sanofi agrees to outsource a significant portion of R&D to Covance in a 10-year deal involving payments of $1.2 billion to $2.2 billion.